Table 2.

Patient demographic and baseline characteristics

ParameterPatients (N = 25)
Sex, n (%)
 Female10 (40)
 Male15 (60)
Age, y*
 Mean (SD)59 (8)
 Median59
 Minimum, maximum45, 72
Race, n (%)
 Black or African American5 (20)
 White19 (76)
 Multiracial1 (4)
HLA status, n (%)
 HLA-A2+25 (100)
NY-ESO-1 status, n (%)
 NY-ESO-1+14 (56)
 NY-ESO-111 (44)
LAGE-1 status, n (%)
 LAGE-1+25 (100)
ECOG performance status, n (%)
 07 (28)
 116 (64)
 22 (8)
Previous therapies, n (%)
 15 (20)
 26 (24)
 34 (16)
 >410 (40)
Cytogenetic abnormalities, n (%)
 ≥112 (48)
 Deletion (13q)8 (32)
 Deletion (17p)1 (5)
 Hypodiploid0 (0)
Transduced cell dose, n (%)
 <1 × 1093 (12)
 1-5 × 10921 (84)
 ≥5 × 1091 (4)
 Median (range)3.1 × 109 (0.5-5.05 × 109)
  • ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.

  • * Age at informed consent/screening.

  • One patient tested positive for LAGE-1 per the laboratory report at screening but was erroneously recorded as LAGE-1 negative in the database, and this was not corrected prior to database lock.

  • Four patients had received a prior autologous stem cell transplant.